242 related articles for article (PubMed ID: 27349451)
1. Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy.
Zheng K; Wu Q; Wang C; Tan W; Mei W
Anticancer Agents Med Chem; 2017; 17(1):29-39. PubMed ID: 27349451
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium(II) complexes as apoptosis inducers by stabilizing c-myc G-quadruplex DNA.
Zhang Z; Wu Q; Wu XH; Sun FY; Chen LM; Chen JC; Yang SL; Mei WJ
Eur J Med Chem; 2014 Jun; 80():316-24. PubMed ID: 24793882
[TBL] [Abstract][Full Text] [Related]
3. Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.
Zhao Z; Luo Z; Wu Q; Zheng W; Feng Y; Chen T
Dalton Trans; 2014 Dec; 43(45):17017-28. PubMed ID: 25087850
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity and mechanism of apoptosis of A549 induced by ruthenium complex.
Sun D; Mou Z; Li N; Zhang W; Wang Y; Yang E; Wang W
J Biol Inorg Chem; 2016 Dec; 21(8):945-956. PubMed ID: 27620172
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Activity and Modes of Action of (arene) ruthenium(II) Complexes Coordinated to C-, N-, and O-ligands.
Biersack B
Mini Rev Med Chem; 2016; 16(10):804-14. PubMed ID: 27161009
[TBL] [Abstract][Full Text] [Related]
6. Arene ruthenium(II) Complexes: The Promising Chemotherapeutic Agent in Inhibiting the Proliferation, Migration and Invasion.
Zheng K; Wu Q; Ding Y; Mei W
Mini Rev Med Chem; 2016; 16(10):796-803. PubMed ID: 26423698
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
Abid M; Shamsi F; Azam A
Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
[TBL] [Abstract][Full Text] [Related]
8. Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways.
Yang L; Zhang J; Wang C; Qin X; Yu Q; Zhou Y; Liu J
Metallomics; 2014 Mar; 6(3):518-31. PubMed ID: 24336978
[TBL] [Abstract][Full Text] [Related]
9. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial fragmentation is an important cellular event induced by ruthenium(II) polypyridyl complexes in osteosarcoma cells.
Du Y; Fu X; Li H; Chen B; Guo Y; Su G; Zhang H; Ning F; Lin Y; Mei W; Chen T
ChemMedChem; 2014 Apr; 9(4):714-8. PubMed ID: 24403015
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cells.
Deng Z; Gao P; Yu L; Ma B; You Y; Chan L; Mei C; Chen T
Biomaterials; 2017 Jun; 129():111-126. PubMed ID: 28340357
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-Sensitive Metal β-Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis.
Lord RM; Hebden AJ; Pask CM; Henderson IR; Allison SJ; Shepherd SL; Phillips RM; McGowan PC
J Med Chem; 2015 Jun; 58(12):4940-53. PubMed ID: 25906293
[TBL] [Abstract][Full Text] [Related]
13. Protein-binding, cytotoxicity in vitro and cell cycle arrest of ruthenium(II) polypyridyl complexes.
Liu SH; Zhu JW; Xu HH; Wang Y; Liu YM; Liang JB; Zhang GQ; Cao DH; Lin YY; Wu Y; Guo QF
Spectrochim Acta A Mol Biomol Spectrosc; 2016 May; 161():77-82. PubMed ID: 26956530
[TBL] [Abstract][Full Text] [Related]
14. Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.
Zhao J; Li S; Wang X; Xu G; Gou S
Inorg Chem; 2019 Feb; 58(3):2208-2217. PubMed ID: 30675781
[TBL] [Abstract][Full Text] [Related]
15. A ruthenium(II) complex capable of inducing and stabilizing bcl-2 G-quadruplex formation as a potential cancer inhibitor.
Zhang J; Yu Q; Li Q; Yang L; Chen L; Zhou Y; Liu J
J Inorg Biochem; 2014 May; 134():1-11. PubMed ID: 24513610
[TBL] [Abstract][Full Text] [Related]
16. Development of Arene Ruthenium Antitumor Complexes.
Su W; Tang Z; Li P
Mini Rev Med Chem; 2016; 16(10):787-95. PubMed ID: 27161008
[TBL] [Abstract][Full Text] [Related]
17. Novel ruthenium(II) triazine complex [Ru(bdpta)(tpy)]
Purushothaman B; Arumugam P; Ju H; Kulsi G; Samson AAS; Song JM
Eur J Med Chem; 2018 Aug; 156():747-759. PubMed ID: 30048924
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry.
Thota S
Mini Rev Med Chem; 2016; 16(10):771. PubMed ID: 27161007
[No Abstract] [Full Text] [Related]
19. Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-Dihydroxypropyl)-formamide Oxoaporphine (FOA): In Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell Apoptosis.
Chen ZF; Qin QP; Qin JL; Zhou J; Li YL; Li N; Liu YC; Liang H
J Med Chem; 2015 Jun; 58(11):4771-89. PubMed ID: 25988535
[TBL] [Abstract][Full Text] [Related]
20. A novel ruthenium(II)-polypyridyl complex inhibits cell proliferation and induces cell apoptosis by impairing DNA damage repair.
Yang Q; Zhang Z; Mei W; Sun F
J Chemother; 2014 Aug; 26(4):235-42. PubMed ID: 24070188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
